Neurovascular medtech startup
Location: Ireland, Galway
Employees: 11-50
Total raised: $53.09M
Founded date: 2018
Investors 3
| Date | Name | Website |
| - | Earlybird ... | earlybird.... |
| 12.02.2022 | Seroba Lif... | seroba-lif... |
| 11.02.2022 | Life Scien... | lspvc.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 13.03.2025 | - | $23.91M | - |
| 09.02.2022 | Series A | $25.74M | - |
| 29.01.2019 | Seed | $3.43M | Earlybird ... |
Mentions in press and media 19
| Date | Title | Description |
| 26.05.2025 | Let'sGetChecked and Tines deals double VC funding in Q1 | Venture capital funding into Irish SMEs doubled to €533m in the first quarter, powered by nine-figure investments in unicorns LetsGetChecked (€150m) and Tines (€115m). Figures from the Irish Venture Capital & Private Equity Association ... |
| 15.03.2025 | Perfuze: €22 Million Raised And Clearance Received For Zipline Access Catheters | Perfuze, a leading medical device company dedicated to advancing stroke treatment, has received FDA 510(k) clearance for its Zipline Access Catheters. This milestone strengthens Perfuze’s growing portfolio of innovative neurovascular device... |
| 13.03.2025 | Perfuze Raises €22M in Additional Funding | Perfuze, a Galway, Ireland-based medical device company, raised €22M in additional funding. The round was led by existing investors including Earlybird, EQT Life Sciences, Seroba and SV Health. Led by CEO Wayne Allen, Perfuze is a medical d... |
| 31.01.2024 | Revolutionizing Stroke Treatment: Can New Medical Tech Result in Superior Clinical Outcomes? | Key Takeaways: Perfuze is an Irish medtech startup focussed on developing innovative treatment for acute ischemic stroke. Founded by Wayne Allen and Liam Mullins, Perfuze’s technology aims to provide superior clinical outcomes and shorter p... |
| 20.12.2023 | Perfuze® Announces FDA Clearances for Novel Neurovascular Aspiration and Access Catheters for Stroke Treatment | Galway, Ireland, December 20, 2023 –Perfuze, a private medical device company dedicated to developing pioneering technology to treat acute ischemic stroke, proudly announces FDA clearance for the Millipede 070 Aspiration Catheter and the 2n... |
| 10.11.2023 | Perfuze® Announces First Stroke Patient Enrolled in the MARRS Pivotal Clinical Trial for the Millipede System. | Galway, Ireland. 2 November 2023. Perfuze, a private medical device company dedicated to developing pioneering technology to treat acute ischemic stroke, announced commencement of enrollment in its pivotal MARRS (Millipede AspiRation for Re... |
| 02.11.2023 | Perfuze Announces First Stroke Patient Enrolled in the MARRS Pivotal Clinical Trial for the Millipede System | Galway, Ireland, November 2, 2023 –Perfuze, a private medical device company dedicated to developing pioneering technology to treat acute ischemic stroke, announced commencement of enrollment in its pivotal MARRS (Millipede AspiRation for R... |
| 17.07.2023 | Earlybird Health's Inaugural Impact & ESG report reveals opportunities and gaps in investor and startups' commitments | Whether you like it or not, you'll be hearing a lot about ESG (Environmental Social Governance) metrics, commitments, and actions from now to forever. Earlybird is one of Europe's most established and active Venture capital firms published ... |
| 09.06.2023 | Perfuze Announces Appointment of New Chair of the Board. | Galway, Ireland. 9 June, 2023. Seroba portfolio company, Perfuze, a medical device company developing next-generation ”super-bore” catheter technology to treat acute ischemic stroke, is pleased to announce the appointment of Hooman Hakami a... |
| 16.02.2023 | Perfuze Announces FDA Clearance and First U.S. Clinical Use of Millipede 088 Access Catheter. | Galway, Ireland. 16 February 2023. Perfuze, a medical device company developing next-generation catheter-based technology to treat acute ischemic stroke, has secured its first product clearance from the U.S. Food and Drug Administration (FD... |
Show more